Antibodies, Bispecific – Page 3

BioNTech Advances PD-L1/VEGF Bispecific Antibody with Encouraging Breast Cancer Trial Results

10 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327/PM8002, Clinical Trials, Combined Modality Therapy, Malignant neoplasm of breast, PD-L1/VEGF

BioNTech, PD-L1/VEGF Bispecific Antibody, BNT327/PM8002, Breast Cancer, Oncology Strategy, Clinical Trials, Combination Therapies

Johnson & Johnson Expands Immunology Portfolio with $1.25B Acquisition of Yellow Jersey Therapeutics

11 months ago talkbio0Tagged Antibodies, Bispecific, Dermatitis, Atopic, Immunology, Johnson and Johnson, NM26, Numab, Yellow Jersey Therapeutics

Johnson & Johnson, Yellow Jersey Therapeutics, NM26, atopic dermatitis, bispecific antibody, immunology, Numab Therapeutics

BioNTech Acquires Biotheus for $800M to Enhance Oncology Strategy with Promising Bispecific Antibody

11 months ago talkbio0Tagged Acquisition, Antibodies, Bispecific, BioNTech, Biotheus, BNT327/PM8002, Cancer Therapeutic Procedure, Neoplasms, PD-L1, Vascular Endothelial Growth Factor A

BioNTech, Biotheus, oncology, bispecific antibody, BNT327/PM8002, PD-L1, VEGF-A, cancer treatment, acquisition

Advancements in Bispecific Antibody Therapies: Recent Deals and Clinical Data on VEGF-Targeting Agents

12 months ago talkbio0Tagged Age related macular degeneration, Agreement, Antibodies, Bispecific, Cancer Therapeutic Procedure, Clinical Trials, Exudative age-related macular degeneration, Neovascular, Royalty, Vascular Endothelial Growth Factor A

Bispecific antibodies, VEGF, neovascular age-related macular degeneration (nAMD), cancer therapy, clinical trials, royalty agreements.

FDA Delays Decision on Merus’ Zenocutuzumab for NRG1+ Lung and Pancreatic Cancer

12 months ago talkbio0Tagged Antibodies, Bispecific, Deferred, Malignant neoplasm of lung, Malignant Neoplasms, Merus, NRG1 gene, Pancreatic carcinoma, United States Food and Drug Administration, zenocutuzumab

Zenocutuzumab, NRG1+ cancer, FDA delay, Merus, lung cancer, pancreatic cancer, bispecific antibody.

A Decade of Progress: Immuno-oncology on the Cusp of a New Era

12 months ago talkbio0Tagged Antibodies, Bispecific, cancer care, Cancer Research, Cancer Therapeutic Procedure, checkpoint inhibitors, immuno-oncology, Immunotherapy

Immuno-oncology, checkpoint inhibitors, bispecific antibodies, cancer treatment, immunotherapy, cancer research, future of cancer care.

Optimizing Expression of Multi-chain and Bispecific Antibodies: Strategies and Considerations

1 year ago talkbio0Tagged Antibodies, Antibodies, Bispecific, Cells, Chinese Hamster Ovary, CHO, Cultured Cell Line, expression vector, Metabolic Engineering, Optimization, production, Recombinants, Stable status

Bispecific Antibodies (bsAbs), Recombinant Antibody Production, Chinese Hamster Ovary (CHO) Cells, Expression Vector Optimization, Metabolic Engineering, Stable Cell Line Development

Johnson & Johnson Highlights Promising Combination of TALVEY and TECVAYLI for Relapsed or Refractory Multiple Myeloma

1 year ago talkbio0Tagged Antibodies, Bispecific, Combined, EMD, Extramedullary Disease in Plasma Cell Myeloma, Frequency of Responses, Refractory Plasma Cell Myeloma, Relapsing course, Response process, Talquetamab, TALVEY, Teclistamab, TECVAYLI

TALVEY (talquetamab), TECVAYLI (teclistamab), Relapsed or Refractory Multiple Myeloma (RRMM), Bispecific Antibody Combination, Extramedullary Disease (EMD), High Response Rates, Durable Responses